| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Tax receivables | - | 696,002 | ||
| Cash and cash equivalents | 5,508,899 | 1,028,324 | ||
| Short-term investments | 13,866,546 | 19,637,812 | ||
| Prepaid expenses and other current assets | 650,429 | 957,095 | ||
| Collaboration receivables | 1,213,226 | 2,418,022 | ||
| Tax and other receivables | 1,454,756 | - | ||
| Total current assets | 22,693,856 | 24,737,255 | ||
| Property and equipment, net | 101,807 | 106,843 | ||
| Restricted cash | 4,520 | 4,461 | ||
| Intangible assets and in-process r&d, net | 6,687,100 | 6,687,100 | ||
| Operating lease right-of-use assets | 318,036 | 349,017 | ||
| Other assets | 58,135 | 61,007 | ||
| Total assets | 29,863,454 | 31,945,683 | ||
| Accounts payable | 241,471 | 282,537 | ||
| Accrued collaboration credit | 29,057 | 219,625 | ||
| Accrued expenses | 2,153,906 | 2,540,493 | ||
| Operating lease liabilities | 155,926 | 143,327 | ||
| Total current liabilities | 2,580,360 | 3,185,982 | ||
| Contingent consideration | 2,883,423 | 4,604,456 | ||
| Deferred tax liability | 490,690 | 490,690 | ||
| Deferred collaboration revenue | 1,250,000 | 1,250,000 | ||
| Non-current operating lease liabilities | 248,239 | 287,079 | ||
| Total non-current liabilities | 4,872,352 | 6,632,225 | ||
| Total liabilities | 7,452,712 | 9,818,207 | ||
| Preferred stock, 0.01 par value 10,000,000 shares authorized 3,750 designated series a, 0 shares issued and outstanding 10,000 designated series b, 0 shares issued and outstanding 10,000 shares designated series c, 0 shares issued and outstanding 20,000 shares designated series d, 7 shares issued and outstanding 1,280 shares designated series e, 0 shares issued and outstanding 3,908 shares designated series f, 420 issued and outstanding at september30, 2025 and december31, 2024, respectively | 4 | 4 | ||
| Common stock, 0.01 par value 150,000,000 shares authorized 3,433,491 and 3,000,788 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 272,006 | 272,006 | ||
| Additional paid-in capital | 170,083,195 | 169,828,797 | ||
| Accumulated deficit | -147,700,755 | -147,727,561 | ||
| Accumulated other comprehensive loss | -243,708 | -245,770 | ||
| Total stockholders equity | 22,410,742 | 22,127,476 | ||
| Total liabilities and stockholders equity | 29,863,454 | 31,945,683 | ||
KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC (KPRX)